دورية أكاديمية
Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.
| العنوان: | Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society. |
|---|---|
| المؤلفون: | Bass AS; Global Discovery Sciences Support, Discovery & Preclinical Sciences, Merck Research Laboratories, 33 Avenue Louis Pasteur, MS: BMB 6-101, Boston, MA 02115, USA. alan.bass@merck.com, Vargas HM, Valentin JP, Kinter LB, Hammond T, Wallis R, Siegl PK, Yamamoto K |
| المصدر: | Journal of pharmacological and toxicological methods [J Pharmacol Toxicol Methods] 2011 Jul-Aug; Vol. 64 (1), pp. 7-15. Date of Electronic Publication: 2011 Jun 12. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 9206091 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-488X (Electronic) Linking ISSN: 10568719 NLM ISO Abbreviation: J Pharmacol Toxicol Methods Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Elsevier, c1992- |
| مواضيع طبية MeSH: | Drug-Related Side Effects and Adverse Reactions*, Drug Evaluation, Preclinical/*trends, Animals ; Drug Discovery/methods ; Drug Evaluation, Preclinical/methods ; Humans ; Risk Assessment/methods ; Societies, Pharmaceutical ; Toxicity Tests/trends |
| مستخلص: | In recognition of the tenth anniversary of the Safety Pharmacology Society (SPS), this review summarizes the significant events of the past 10years that have led to the birth, growth and evolution the SPS and presents a roadmap to the immediate-, intermediate- and long-term future of the SPS. The review discusses (i) the rationale for an optimal non-clinical Safety Pharmacology testing, (ii) the evolution of Safety Pharmacology over the last decade, (iii) its impact on drug discovery and development, (iv) the merits of adopting an integrated risk assessment approach, (v) the translation of non-clinical findings to humans and finally (vi) the future challenges and opportunities facing this discipline. Such challenges include the emergence of new molecular targets and new approaches to treat diseases, the rapid development of science and technologies, the growing regulatory concerns and associated number of guidance documents, and the need to train and educate the next generation of safety pharmacologist. (Copyright © 2011 Elsevier Inc. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20110622 Date Completed: 20120214 Latest Revision: 20131121 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.vascn.2011.05.006 |
| PMID: | 21689769 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1873-488X |
|---|---|
| DOI: | 10.1016/j.vascn.2011.05.006 |